Peer-reviewed veterinary case report
Masitinib treatment results for dogs with visible mast cell tumors
By Grant, J et al.·Published in The Journal of small animal practice·2016·Small Animal Oncology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
- Species:
- dog
Plain-English summary
A group of 39 dogs with noticeable mast cell tumors, a type of skin cancer, were treated with a medication called masitinib (Masivet). Most of the dogs showed improvement, with 15 achieving complete tumor disappearance and 17 showing partial improvement. While some dogs experienced side effects like vomiting and elevated liver enzymes, masitinib was generally well-tolerated. On average, dogs lived about 159 days after starting treatment, with some living much longer.
People also search for: dog mast cell tumor treatment · masitinib for dog cancer · side effects of masitinib in dogs
Abstract
OBJECTIVES: To retrospectively evaluate the clinical response and toxicity associated with masitinib mesylate (Masivet®) treatment of macroscopic mast cell tumours in the dog. METHODS: Retrospective review of medical records of 39 dogs that had undergone treatment with masitinib for macroscopic mast cell tumours. Patient signalment, tumour location, tumour grade, tumour stage, previous treatments, concurrent medications, dose of masitinib, side effects, response, time to tumour progression, survival time and cause of death were documented. Response was assessed according to RECIST criteria. RESULTS: Clinical response was observed in 32 (82·1%) dogs receiving masitinib, with 15 dogs (38·5%) exhibiting a complete response and 17 dogs (43·6%) achieving a partial response. The median time to progression was 79 days (range: 14 to 667 days). Adverse effects were seen in 25 dogs (64·1%) with serum alanine aminotransferase elevation (n=9; 23·1%) and vomiting (n=6; 15·4%) being most common. Median survival time following initiation of masitinib was 159 days (range: 14 to 1339). CLINICAL SIGNIFICANCE: Masitinib appears to be a well-tolerated and effective drug against macroscopic mast cell tumours.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27136424/